The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.

Earlier in December, telehealth company Ro announced a partnership with Eli Lilly to offer a half-price version of Zepbound, Lilly's brand-name tirzepatide product. The cheaper option is sold in ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

If you’re taking tirzepatide for weight loss, you might find the drug isn’t covered by insurance. It comes with a hefty price tag, which can add up if you take the drug for a long time.

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...